Cardiome And Astellas Announce Regulat... ( NASDAQ: CR...)

Cardiome And Astellas Announce Regulatory Update

Date:1/21/2008

NASDAQ: CRME TSX: COM

VANCOUVER and DEERFIELD, IL, Jan. 21 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") today announced that they have been informed by the U.S. Food and Drug Administration (FDA) that a decision has not yet been made regarding the New Drug Application (NDA) for KYNAPID(TM) (vernakalant hydrochloride). The FDA did not provide an action letter prior to the PDUFA date of January 19, 2008.

"While we look forward to the FDA reaching a decision, we respect their need for additional time to review the KYNAPID NDA," said William E. Fitzsimmons, PharmD, Senior Vice President, Research & Development at Astellas. "Astellas and Cardiome strongly believe in the therapeutic value of KYNAPID based on clinical trial data and are confident it will be an important therapy in the treatment of atrial fibrillation."

In October 2003, Cardiome granted Astellas Pharma US, Inc. an exclusive license to develop and commercialize KYNAPID in North America. Cardiome has retained all rights to the intravenous formulations outside of Canada, the U.S. and Mexico. The NDA for KYNAPID, based on a five-year clinical development program, was submitted in December 2006. In December 2007, the FDA Cardiovascular and Renal Drugs Advisory Committee voted 6-2 in favour of recommending to the FDA that KYNAPID be approved for the rapid conversion of acute AF to sinus rhythm.

About Cardiome

Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two late-stage clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), a Phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C, and a pre-clinical program directed at improving cardiovascular function.

Vernakalant (iv) is the intravenous formulation of an investigational drug being evaluated f
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Cardiome to Hold Investor Update Call
2. Cardiome Updates Guidance
3. Cardiome Initiates Phase 1 Study for GED-aPC
4. Cardiome To Release Third Quarter Results
5. Cardiome to Present at CIBC Conference
6. Cardiome to Present at ThinkEquity Conference
7. Cardiome to Present at Bear Stearns Conference
8. Pharmacyclics Announces Conference Call to Discuss Second Quarter 2008 Financial Results
9. Cardica to Announce Fiscal 2008 Second Quarter Financial Results on Thursday, January 24, 2008
10. Lance Armstrong and 17th U.S. Surgeon General Carmona Announce National Call to Action in the War Against Cancer
11. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed

Post Your Comments:

Cardiome And Astellas Announce Regulat...( NASDAQ: CR...),Health